

# Exploring *Mycobacterium microtii* Upcoming Participant in Mycobacterial Infections

Chang Weng\*

Department of Microbiology, University of Bristol, Bristol, England

## DESCRIPTION

*Mycobacterium microtii* is a lesser-known member of the mycobacterial genus, yet its significance is increasingly recognized in the realm of infectious diseases. As an emerging pathogen, *Mycobacterium microtii* presents unique challenges in diagnosis, treatment, and understanding its epidemiology [1]. In this article, we delve into the characteristics, clinical implications, diagnosis, treatment, and research surrounding *Mycobacterium microtii* infections.

### Understanding *Mycobacterium microtii*

*Mycobacterium microtii* is a slow-growing, acid-fast bacterium belonging to the genus *Mycobacterium*. It is characterized by its rod-shaped morphology and ability to survive in diverse environmental conditions [2]. While it shares similarities with other mycobacterial species, such as *Mycobacterium tuberculosis* and *Mycobacterium avium* complex (MAC), *Mycobacterium microtii* possesses unique genetic and biochemical features that distinguish it as a separate species.

### Clinical implications

Although less commonly encountered than other mycobacterial species, *Mycobacterium microtii* has been implicated in a range of clinical manifestations, including pulmonary and extrapulmonary infections [3]. Pulmonary infections may present with symptoms such as cough, fever, weight loss, and fatigue, while extrapulmonary infections can affect various organs and tissues, leading to a diverse array of symptoms depending on the site of infection [4].

### Diagnosis

Diagnosing *Mycobacterium microtii* infections can be challenging due to its slow growth rate and similarities with other mycobacterial species. Laboratory methods such as culture, Nucleic Acid Amplification Tests (NAATs), and molecular typing techniques may be employed to isolate and identify the bacterium from clinical specimens [5]. However, specialized

expertise and resources are often required to accurately diagnose *Mycobacterium microtii* infections, highlighting the need for improved diagnostic tools and protocols.

### Treatment

Antimicrobial therapy is the mainstay of treatment for *Mycobacterium microtii* infections, typically involving a combination of antibiotics take to the susceptibility profile of the infecting strain [6]. Due to its slow growth and intrinsic resistance to certain antibiotics, such as isoniazid and pyrazinamide, *Mycobacterium microtii* may require prolonged treatment regimens compared to other mycobacterial infections. Close monitoring of treatment response and regular follow-up are essential to ensure successful outcomes and prevent relapse [7].

### Epidemiology and factors

The epidemiology of *Mycobacterium microtii* infections remains poorly understood, with limited data available on its prevalence, distribution, and transmission dynamics [8]. While cases have been reported worldwide, certain geographic regions, such as Europe and North America, appear to have a higher burden of infection. Risk factors for *Mycobacterium microtii* infections may include underlying immunosuppression, comorbidities, environmental exposures, and healthcare-associated transmission [9].

### Research and future directions

As an emerging pathogen, *Mycobacterium microtii* presents numerous opportunities for research and scientific inquiry. Studies investigating its genetic diversity, virulence factors, antibiotic resistance mechanisms, and host-pathogen interactions are essential for advancing our understanding of the bacterium and informing strategies for diagnosis, treatment, and prevention. Additionally, efforts to develop novel diagnostic assays, therapeutic agents, and vaccines targeting *Mycobacterium microtii* are warranted to address the evolving challenges posed by this emerging pathogen [10].

**Correspondence to:** Chang Weng, Department of Microbiology, University of Bristol, Bristol, England, E-mail: 8596@45896.co.uk

**Received:** 03-Jan-2024, Manuscript No. MDTL-24-29591; **Editor assigned:** 05-Jan-2024, Pre QC No. MDTL-24-29591 (PQ); **Reviewed:** 19-Jan-2024, QC No. MDTL-24-29591; **Revised:** 26-Jan-2024, Manuscript No. MDTL-24-29591 (R); **Published:** 02-Feb-2024, DOI: 10.35248/2161-1068.24.14.426

**Citation:** Weng C (2024) Exploring *Mycobacterium microtii* Upcoming Participant in Mycobacterial Infections. *Mycobact Dis*.14:426.

**Copyright:** © 2024 Weng C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## CONCLUSION

*Mycobacterium microtii* represents an intriguing yet understudied member of the mycobacterial genus, with implications for human health and clinical practice. While its clinical significance and epidemiology continue to be elucidated, efforts to improve diagnostic capabilities, treatment outcomes, and public health interventions are essential for addressing the challenges posed by *Mycobacterium microtii* infections. By fostering collaborative research efforts and interdisciplinary approaches, we can enhance our understanding of this emerging pathogen and develop effective strategies for its management and control.

## REFERENCES

1. Gupta RS. Impact of genomics on clarifying the evolutionary relationships amongst mycobacteria: Identification of molecular signatures specific for the tuberculosis-complex of bacteria with potential applications for novel diagnostics and therapeutics. *High Throughput*. 2018;7(4):31.
2. Wiker HG. MPB70 and MPB83—major antigens of *Mycobacterium bovis*. *Scand J Immunol*. 2009;69(6):492-499.
3. Ghanavi J, Farnia P, Farnia P, Velayati AA. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections. *Int J Mycobacteriol*. 2021;10(4):349-357.
4. Mancuso G, Midiri A, de Gaetano S, Ponzo E, Biondo C. Tackling drug-resistant tuberculosis: New challenges from the old pathogen *Mycobacterium tuberculosis*. *Microorganisms*. 2023;11(9):2277.
5. Madacki J, Fiol GM, Brosch R. Update on the virulence factors of the obligate pathogen *Mycobacterium tuberculosis* and related tuberculosis-causing mycobacteria. *Infect Genet Evol*. 2019;72:67-77.
6. Rastogi N, Legrand E, Sola C. The mycobacteria: An introduction to nomenclature and pathogenesis. *Rev Sci Tech*. 2001;20(1):21-54.
7. Sayes F, Blanc C, Ates LS, Deboosere N, Orgeur M, Le Chevalier F, et al. Multiplexed quantitation of intraphagocyte *Mycobacterium tuberculosis* secreted protein effectors. *Cell Rep*. 2018;23(4):1072-1084.
8. Bos KI, Harkins KM, Herbig A, Coscolla M, Weber N, Comas I, et al. Pre-Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. *Nature*. 2014;514(7523):494-497.
9. Michelet L, Richomme C, Réveillaud E, de Cruz K, Moyen JL, Boschioli ML. *Mycobacterium microti* infection in red foxes in France. *Microorganisms*. 2021;9(6):1257.
10. Khusro A, Aarti C, Agastian P. Anti-tubercular peptides: A quest of future therapeutic weapon to combat tuberculosis. *Asian Pac J Trop Med*. 2016;9(11):1023-1034.